- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/30 - Oxygen atoms
Patent holdings for IPC class C07D 213/30
Total number of patents in this class: 635
10-year publication summary
|
59
|
52
|
40
|
44
|
37
|
32
|
33
|
29
|
20
|
21
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4849 |
12 |
| Abbvie Inc. | 1806 |
12 |
| Sumitomo Chemical Company, Limited | 9079 |
11 |
| Unigen, Inc. | 110 |
11 |
| JNC Corporation | 1568 |
9 |
| Global Blood Therapeutics, Inc. | 183 |
8 |
| JNC Petrochemical Corporation | 400 |
8 |
| Purdue Pharma L.P. | 502 |
8 |
| Mycovia Pharmaceuticals, Inc. | 41 |
8 |
| Novartis AG | 10721 |
7 |
| The Regents of the University of California | 20108 |
6 |
| AstraZeneca AB | 2886 |
6 |
| Chiesi Farmaceutici S.p.A. | 971 |
6 |
| Calico Life Sciences LLC | 100 |
6 |
| Merck Sharp & Dohme LLC | 3753 |
6 |
| Allergan, Inc. | 2337 |
5 |
| Galderma Research & Development | 398 |
5 |
| F. Hoffmann-La Roche AG | 7948 |
4 |
| BASF SE | 21017 |
4 |
| LG Chem, Ltd. | 17676 |
4 |
| Other owners | 489 |